MAPT and Alzheimer disease: We found that age and APOE genotype, but not ADPRS (based on cases having clinical diagnosis of AD), were significant predictors of continuous p‐tau217 levels but also ADNPC, as indicated by abnormal levels of plasma p‐tau217 using published cutoffs for amyloid and tau positivity.1